Tirzepatide Dosing: How the FDA Titration Ladder Works

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub — plain-language guidance on GLP-1 therapies, weight-management protocols, and the genetic variables behind every metabolic decision.

Questions about tirzepatide dosing usually come from someone already on the ladder or approaching a new rung. This page reports what the FDA-approved label describes about the titration schedule and what patients tend to experience while adjusting. It offers no prescribing or titration instruction — that judgment belongs to your prescribing provider alone.

Dosing is a schedule, not a single number

There is no one tirzepatide dose; there is a titration ladder. The compound is titrated per the FDA-approved label starting at 2.5 mg weekly and moving through 5, 7.5, 10, 12.5, and 15 mg at minimum intervals. Where a given person sits on that ladder is a clinical decision a provider makes based on tolerability and response, not a preference selected from a list.

The logic behind gradual increases

The ladder climbs slowly on purpose. Beginning at a low dose and stepping up over time lets the body acclimate and helps blunt the gastrointestinal effects that peak just after each increase.

Adjusting versus advancing

A provider may hold at a dose to let symptoms settle before advancing, treating the schedule as a floor of minimum intervals rather than a fixed timetable.

Reaching a maintenance dose

Some patients settle at a dose that meets their clinical goals and stay there long-term rather than climbing to the top rung.

What adjusting feels like for most people

Gastrointestinal symptoms — nausea, mild vomiting, transient constipation or diarrhea — are the most commonly reported experiences during any dose step, and they are usually strongest in the first weeks after a change. Appetite suppression, earlier satiety, and shifts in meal portions are also common. These are individual experiences, and clinical outcomes vary widely from one person to the next.

How intervals between steps are decided

Titration intervals are specified in each product's FDA label, typically around four weeks between steps, then adjusted by the prescribing provider based on tolerability and clinical response. Significant gastrointestinal symptoms may lead a provider to extend time at the current dose. A well-tolerated dose that has not yet met clinical goals may prompt advancement per the label.

Warning signs at any dose

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Contact a provider for severe or persistent abdominal pain that may indicate pancreatitis, right-upper-quadrant pain with fever that may indicate gallbladder disease, persistent vomiting with dehydration, signs of hypoglycemia, or any allergic reaction. Severe symptoms warrant urgent or emergency care.

Talking to your provider about dosing

Because dosing decisions rest with your provider, the most useful thing you can bring is good information about your own experience. Keeping a simple record of how each step has felt, when symptoms appeared, how long they lasted, and whether they eased gives a clinician the detail needed to judge whether to hold or advance. It also helps to note practical effects like appetite and meal-portion changes, since those inform the picture alongside side effects. Ask directly about the minimum interval before the next step and what would prompt staying put longer. Framing the appointment around observations rather than a target dose keeps the conversation grounded in tolerability and clinical response, which is exactly how the label schedule is meant to be applied to an individual.

Why the same dosing feels different person to person

The label schedule is uniform, but the human response to it is not, because metabolism is individual. The Precision Peptide Genetic Test examines 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology. It is not a pharmacogenomic test and never predicts response to any specific dose or medication; it gives upstream context that holds at every step. See how PlexusDx applies it across its Weight Management Protocols. PlexusDx does not sell other GLP-1 category compounds such as retatrutide, which is investigational and not FDA-approved.

Frequently Asked Questions

How does tirzepatide dosing progress?

Per the FDA-approved label, tirzepatide is titrated starting at 2.5 mg weekly and moving through 5, 7.5, 10, 12.5, and 15 mg at minimum intervals. Your prescribing provider guides where your dose sits along that ladder based on tolerability and clinical response, not a self-selected target.

How long do I stay on one dose?

Titration intervals in the FDA label are typically a minimum of about four weeks between steps, then modified by the prescribing provider based on tolerability and response. Some patients remain at one dose long-term as a maintenance dose, while others continue advancing along the label schedule under guidance.

What side effects should I watch for while adjusting?

Gastrointestinal symptoms — nausea, vomiting, diarrhea, constipation — are most common at any dose step. Contact your provider for severe abdominal pain, persistent vomiting with dehydration, right-upper-quadrant pain with fever, or any allergic reaction. All GLP-1 pathway compounds carry the class boxed warning for thyroid C-cell tumor risk.

Can genetics tell me my ideal dose?

No. The Precision Peptide Genetic Test does not predict response to any specific dose or medication. It analyzes pathway-level variants in genes such as FTO, GLP1R, MC4R, and TCF7L2 that shape baseline metabolism, providing upstream context that applies across the titration ladder rather than a dosing recommendation.

Keep reading across the PlexusDx Education Hub for more evidence-based GLP-1 and metabolic-health explainers.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.